» Articles » PMID: 29205833

Monocarboxylate Transporter 1 and the Vulnerability of Oligodendrocyte Lineage Cells to Metabolic Stresses

Overview
Specialties Neurology
Pharmacology
Date 2017 Dec 6
PMID 29205833
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: Oligodendrocytes, especially oligodendrocyte precursor cells, are known to be sensitive to hypoxic and metabolic stresses. Vulnerability of oligodendrocytes is considered a contributing factor to white matter dysfunction. However, little is known about the energy processing characteristics of oligodendrocyte lineage cells under basal and metabolic stress conditions. The aim of this study was to identify the energy requirements and cellular responses of oligodendrocytes at different developmental stages.

Methods: We compared the metabolic stress responses between myelinating oligodendrocytes (OLs) and oligodendrocyte precursor cells (OPCs). Differential regulation of cellular response was also investigated.

Results: We found that, following cerebral ischemia, monocarboxylate transporter 1 (MCT1) expression was upregulated in the peri-infarct striatum but not in the cortex of the brain. In vitro ischemia models were used to induce oligodendrocyte stress as well. An increase in MCT1 expression was detected in OPCs after a mild oxygen-glucose deprivation. Double-labeled immunohistochemical analysis revealed that OPCs and OLs responded differently to metabolic stresses and that the susceptibility to metabolic stresses of OPCs and OLs was associated with their distinct expression profiles of MCT1.

Conclusion: Taken together, this study shows that MCT1 plays a role in the responses of OPCs and OLs to metabolic and ischemic stresses and suggests that redistribution of energy substrates is a determinant in white matter injury.

Citing Articles

Should We Consider Neurodegeneration by Itself or in a Triangulation with Neuroinflammation and Demyelination? The Example of Multiple Sclerosis and Beyond.

Perdaens O, van Pesch V Int J Mol Sci. 2024; 25(23.

PMID: 39684351 PMC: 11641818. DOI: 10.3390/ijms252312637.


From BBB to PPP: Bioenergetic requirements and challenges for oligodendrocytes in health and disease.

Fernandes M, Pernin F, Antel J, Kennedy T J Neurochem. 2024; 169(1):e16219.

PMID: 39253904 PMC: 11657931. DOI: 10.1111/jnc.16219.


Glycolytic dysregulation in Alzheimer's disease: unveiling new avenues for understanding pathogenesis and improving therapy.

Wu Y, Yang L, Jiang W, Zhang X, Yao Z Neural Regen Res. 2024; 20(8):2264-2278.

PMID: 39101629 PMC: 11759019. DOI: 10.4103/NRR.NRR-D-24-00190.


Oligodendroglia Confer Neuroprotection to NSC-34 Motor Neuronal Cells Against the Toxic Insults of Cerebrospinal Fluid from Sporadic Amyotrophic Lateral Sclerosis Patients.

Ramya V, Sarkar N, Bhagat S, Pradhan R, Varghese A, Nalini A Mol Neurobiol. 2023; 60(9):4855-4871.

PMID: 37184766 DOI: 10.1007/s12035-023-03375-y.


Cerebral Ischemic Preconditioning Aggravates Death of Oligodendrocytes.

Guan T, Guo Y, Li C, Zhou T, Yu Q, Yang C Biomolecules. 2022; 12(12).

PMID: 36551300 PMC: 9776065. DOI: 10.3390/biom12121872.


References
1.
Seidl A . Regulation of conduction time along axons. Neuroscience. 2013; 276:126-34. PMC: 3849146. DOI: 10.1016/j.neuroscience.2013.06.047. View

2.
Saab A, Tzvetavona I, Trevisiol A, Baltan S, Dibaj P, Kusch K . Oligodendroglial NMDA Receptors Regulate Glucose Import and Axonal Energy Metabolism. Neuron. 2016; 91(1):119-32. PMC: 9084537. DOI: 10.1016/j.neuron.2016.05.016. View

3.
Kassis H, Chopp M, Liu X, Shehadah A, Roberts C, Zhang Z . Histone deacetylase expression in white matter oligodendrocytes after stroke. Neurochem Int. 2014; 77:17-23. PMC: 4332872. DOI: 10.1016/j.neuint.2014.03.006. View

4.
Sairanen T, Karjalainen-Lindsberg M, Paetau A, Ijas P, Lindsberg P . Apoptosis dominant in the periinfarct area of human ischaemic stroke--a possible target of antiapoptotic treatments. Brain. 2005; 129(Pt 1):189-99. DOI: 10.1093/brain/awh645. View

5.
Bergersen L . Lactate transport and signaling in the brain: potential therapeutic targets and roles in body-brain interaction. J Cereb Blood Flow Metab. 2014; 35(2):176-85. PMC: 4426752. DOI: 10.1038/jcbfm.2014.206. View